Cargando…
HbA1c Screening for Diabetes in Patients with Acute Coronary Syndrome: A Worthwhile Test or a Pitfall?
Background: Diagnostic concordance between HbA1c and other glucose-based tests is imperfect, and data on this problem in acute coronary syndrome (ACS) are still lacking. The aim of this study was to identify undiagnosed glucose abnormalities in ACS patients, and to compare the effectiveness and cons...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509534/ https://www.ncbi.nlm.nih.gov/pubmed/34640351 http://dx.doi.org/10.3390/jcm10194334 |
_version_ | 1784582364974809088 |
---|---|
author | Józwa, Robert Bryśkiewicz, Marta Safranow, Krzysztof Majkowska, Liliana |
author_facet | Józwa, Robert Bryśkiewicz, Marta Safranow, Krzysztof Majkowska, Liliana |
author_sort | Józwa, Robert |
collection | PubMed |
description | Background: Diagnostic concordance between HbA1c and other glucose-based tests is imperfect, and data on this problem in acute coronary syndrome (ACS) are still lacking. The aim of this study was to identify undiagnosed glucose abnormalities in ACS patients, and to compare the effectiveness and consistency of the diagnostic screening based on HbA1c to the oral glucose tolerance test (OGTT). Methods: The study group consisted of 121 ACS patients, mean age 62.3 ± 11.6 years, without known glucose abnormalities. HbA1c, admission and fasting plasma glucose in the first days of hospitalization were assessed and referred to the results of OGTT performed two weeks after discharge. Results: OGTT identified normoglycemia in 45%, pre-diabetes in 39.4%, and diabetes in 15.6%, while HbA1c revealed these categories in 39.7%, 51.2%, and 9.1%, respectively. With an HbA1c cut-off ≥6.5% (48 mmol/mol) diagnostic for diabetes, the sensitivity of the method was 41%, while specificity was 98%, compared to the OGTT. The optimal HbA1c cut-off value at the crossing of sensitivity and specificity curves was 5.9%. The HbA1c value recommended for the diagnosis of pre-diabetes and optimal cut-off point were the same (5.7%). Conclusions: Using HbA1c without OGTT in an early but stable phase of ACS may result in a significant underdiagnosis of diabetes. |
format | Online Article Text |
id | pubmed-8509534 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85095342021-10-13 HbA1c Screening for Diabetes in Patients with Acute Coronary Syndrome: A Worthwhile Test or a Pitfall? Józwa, Robert Bryśkiewicz, Marta Safranow, Krzysztof Majkowska, Liliana J Clin Med Article Background: Diagnostic concordance between HbA1c and other glucose-based tests is imperfect, and data on this problem in acute coronary syndrome (ACS) are still lacking. The aim of this study was to identify undiagnosed glucose abnormalities in ACS patients, and to compare the effectiveness and consistency of the diagnostic screening based on HbA1c to the oral glucose tolerance test (OGTT). Methods: The study group consisted of 121 ACS patients, mean age 62.3 ± 11.6 years, without known glucose abnormalities. HbA1c, admission and fasting plasma glucose in the first days of hospitalization were assessed and referred to the results of OGTT performed two weeks after discharge. Results: OGTT identified normoglycemia in 45%, pre-diabetes in 39.4%, and diabetes in 15.6%, while HbA1c revealed these categories in 39.7%, 51.2%, and 9.1%, respectively. With an HbA1c cut-off ≥6.5% (48 mmol/mol) diagnostic for diabetes, the sensitivity of the method was 41%, while specificity was 98%, compared to the OGTT. The optimal HbA1c cut-off value at the crossing of sensitivity and specificity curves was 5.9%. The HbA1c value recommended for the diagnosis of pre-diabetes and optimal cut-off point were the same (5.7%). Conclusions: Using HbA1c without OGTT in an early but stable phase of ACS may result in a significant underdiagnosis of diabetes. MDPI 2021-09-23 /pmc/articles/PMC8509534/ /pubmed/34640351 http://dx.doi.org/10.3390/jcm10194334 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Józwa, Robert Bryśkiewicz, Marta Safranow, Krzysztof Majkowska, Liliana HbA1c Screening for Diabetes in Patients with Acute Coronary Syndrome: A Worthwhile Test or a Pitfall? |
title | HbA1c Screening for Diabetes in Patients with Acute Coronary Syndrome: A Worthwhile Test or a Pitfall? |
title_full | HbA1c Screening for Diabetes in Patients with Acute Coronary Syndrome: A Worthwhile Test or a Pitfall? |
title_fullStr | HbA1c Screening for Diabetes in Patients with Acute Coronary Syndrome: A Worthwhile Test or a Pitfall? |
title_full_unstemmed | HbA1c Screening for Diabetes in Patients with Acute Coronary Syndrome: A Worthwhile Test or a Pitfall? |
title_short | HbA1c Screening for Diabetes in Patients with Acute Coronary Syndrome: A Worthwhile Test or a Pitfall? |
title_sort | hba1c screening for diabetes in patients with acute coronary syndrome: a worthwhile test or a pitfall? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509534/ https://www.ncbi.nlm.nih.gov/pubmed/34640351 http://dx.doi.org/10.3390/jcm10194334 |
work_keys_str_mv | AT jozwarobert hba1cscreeningfordiabetesinpatientswithacutecoronarysyndromeaworthwhiletestorapitfall AT bryskiewiczmarta hba1cscreeningfordiabetesinpatientswithacutecoronarysyndromeaworthwhiletestorapitfall AT safranowkrzysztof hba1cscreeningfordiabetesinpatientswithacutecoronarysyndromeaworthwhiletestorapitfall AT majkowskaliliana hba1cscreeningfordiabetesinpatientswithacutecoronarysyndromeaworthwhiletestorapitfall |